On March 2, UK Prime Minister Theresa May delivered a speech on the future of the United Kingdom’s relationship with the European Union, calling for the United Kingdom to remain a member of the European Medicines Agency (EMA), and saying that the United Kingdom could commit to abiding by the rules of the EMA and “making an appropriate financial contribution” to the agency.
On March 2, UK Prime Minister Theresa May delivered a speech on the future of the United Kingdom’s relationship with the European Union, calling for the United Kingdom to remain a member of the European Medicines Agency (EMA), and saying that the United Kingdom could commit to abiding by the rules of the EMA and “making an appropriate financial contribution” to the agency.
“Membership of the [EMA] would mean investment in new innovative medicines continuing in the [United Kingdom], and it would mean these medicines getting to patients faster as firms prioritize larger markets when they start the lengthy process of seeking authorizations,” said May. “But it would also be good for the [European Union], because the UK regulator assesses more new medicines than any other member state. And the [European Union] would continue to access the expertise of the [United Kingdom’s] world-leading universities.”
At the same time, May left open the possibility that the nation might not accept European rules on remaining part of the EMA: “Of course, Parliament would remain ultimately sovereign. It could decide not to accept these rules, but with consequences for our membership of the relevant agency and linked market access rights.”
In response to May’s speech, Bioindustry Association (BIA) CEO Steve Bates said that “It’s good to see [May] articulating the practical dynamics of our industry of the future,” and that “Her language reflects the work that the BIA has undertaken on regulatory cooperation since before the referendum, as well as the desire of patient, [National Health Service] Confederation and European coalitions.”
In delivering the Association of the British Pharmaceutical Industry’s (ABPI) response to the speech, Mike Thompson, ABPI’s chief executive, said, “Every month, 45 million packs of medicines move from the [United Kingdom] to the [European Union]—and 37 million come the other way. That is why the prime minister’s commitment to seek cooperation on medicines regulation would be the best outcome for patients, not just in the [United Kingdom] but across Europe.”
However, cautioned Thompson, cooperation on regulatory matters is only part of the challenge posed by Brexit; ensuring that the supply of medicines remains uninterrupted throughout the United Kingdom and EU territories is critical. Thompson went on to call for establishment of a transition period for the pharmaceutical industry to move to a new framework, and underscored the importance of securing the ability to freely trade and transport medicines across borders, to establish predictable access to funding for scientific research, to form an immigration framework that will allow for skilled professionals from around the world to work in the pharmaceutical industry.
Meanwhile, the EMA is preparing for its relocation from London, United Kingdom, to Amsterdam, the Netherlands, prior for March 29, 2019. Today, the EMA published a new, interactive tracking tool that shows the major milestones of and deliverables associated with the move, with the goal of “giving stakeholders and the public full visibility of the relocation project.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.